Incyclinide
Clinical data | |
---|---|
Trade names | Metastat (proposed) |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H17NO7 |
Molar mass | 371.345 g·mol−1 |
3D model (JSmol) | |
| |
|
Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea,[1] various tumours, allergic and inflammatory diseases and a number of other conditions. The drug has no antibiotic properties.[2][3][4]
Mechanism of action
Like other tetracyclines, incyclinide inhibits matrix metalloproteinases.[2]
References
- ^ Reuters: CollaGenex says incyclinide ineffective for rosacea
- ^ a b Viera, MH, Perez, OA, Berman, B. "Incyclinide". Drugs of the Future. 32 (3): 209–214.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ H. Spreitzer (2 July 2007). "Neue Wirkstoffe - Incyclinid". Österreichische Apothekerzeitung (in German) (14/2007): 655.
- ^ ClinicalTrials.gov: Incyclinide